DEA Significantly Increases 2023 Production Quotas
Post# of 135
(Total Views: 225)
Posted On: 10/21/2022 5:36:34 PM
DEA Significantly Increases 2023 Production Quotas for Cannabis, Psychedelics
The U.S. Drug Enforcement Administration (DEA) has proposed a significant increase to the cannabis and psychedelics quota to be produced legally for research in 2023. In a new notice, the federal agency proposed that the new quota for marijuana be increased to 6.7 million grams. This is twice as much as its quota for 2022, which was 3.2 million grams, and more than three times its 2021 quota, which stood at 2 million grams.
Increasing the marijuana quota will be easy, especially since the federal agency authorized additional marijuana manufacturers earlier this year. These approved producers can now apply for contracts to be federal cannabis suppliers for research purposes, under the National Institute on Drug Abuse.
The DEA has also been increasing the production quota for psychedelics such as mescaline, LSD and psilocin, as interest in the therapeutic potential of these drugs increases. More localities and states enacting reforms these last few years have also played a role in this.
While the production quota for psilocybin will remain 8,000 grams next year, that of psilocybin will increase to 8,000 grams from 4,000 grams. Psilocybin is a key ingredient found in hallucinogenic mushrooms.
In its statement, the federal agency stated that there had been a considerable increase in the use of hallucinogenic substances under schedule I for clinical trials and research purposes. It also explained that it had received and approved new applications for registration from manufacturers and new registration applications for Schedule I researchers to cultivate, synthesize and prepare dosage forms that contained certain Schedule I drugs for research purposes.
The DEA will also be increasing LSD’s production quota in 2023 to 1,200 grams, which is more than double its 2022 production quota of 500 grams. This is in addition to increasing its DMT quota from 2,550 grams to 6,000 grams. Furthermore, the federal agency has proposed that the production quota of mescaline be increased to 1,200 grams from a mere 100 grams.
Mescaline is a hallucinogen that naturally occurs in psychedelic cacti such as peyote. It is usually excluded from resolutions to decriminalize entheogenic substances due to concerns about overharvesting, because this threatens the supply for Indigenous peoples who use the hallucinogen in their rituals. However, the hallucinogen can also be synthetically produced.
In its statement, the DEA added that the proposed quotas for next year reflect the quantities it believed were necessary to meet the scientific, medical, industrial and research needs of the United States, which include lawful export requirements as well as establishing and maintaining reserve stocks.
These increased production quotas suggest that the academia and industry actors such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are stepping up their efforts to study these substances and find ways through which they can be leveraged for human health.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
The U.S. Drug Enforcement Administration (DEA) has proposed a significant increase to the cannabis and psychedelics quota to be produced legally for research in 2023. In a new notice, the federal agency proposed that the new quota for marijuana be increased to 6.7 million grams. This is twice as much as its quota for 2022, which was 3.2 million grams, and more than three times its 2021 quota, which stood at 2 million grams.
Increasing the marijuana quota will be easy, especially since the federal agency authorized additional marijuana manufacturers earlier this year. These approved producers can now apply for contracts to be federal cannabis suppliers for research purposes, under the National Institute on Drug Abuse.
The DEA has also been increasing the production quota for psychedelics such as mescaline, LSD and psilocin, as interest in the therapeutic potential of these drugs increases. More localities and states enacting reforms these last few years have also played a role in this.
While the production quota for psilocybin will remain 8,000 grams next year, that of psilocybin will increase to 8,000 grams from 4,000 grams. Psilocybin is a key ingredient found in hallucinogenic mushrooms.
In its statement, the federal agency stated that there had been a considerable increase in the use of hallucinogenic substances under schedule I for clinical trials and research purposes. It also explained that it had received and approved new applications for registration from manufacturers and new registration applications for Schedule I researchers to cultivate, synthesize and prepare dosage forms that contained certain Schedule I drugs for research purposes.
The DEA will also be increasing LSD’s production quota in 2023 to 1,200 grams, which is more than double its 2022 production quota of 500 grams. This is in addition to increasing its DMT quota from 2,550 grams to 6,000 grams. Furthermore, the federal agency has proposed that the production quota of mescaline be increased to 1,200 grams from a mere 100 grams.
Mescaline is a hallucinogen that naturally occurs in psychedelic cacti such as peyote. It is usually excluded from resolutions to decriminalize entheogenic substances due to concerns about overharvesting, because this threatens the supply for Indigenous peoples who use the hallucinogen in their rituals. However, the hallucinogen can also be synthetically produced.
In its statement, the DEA added that the proposed quotas for next year reflect the quantities it believed were necessary to meet the scientific, medical, industrial and research needs of the United States, which include lawful export requirements as well as establishing and maintaining reserve stocks.
These increased production quotas suggest that the academia and industry actors such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are stepping up their efforts to study these substances and find ways through which they can be leveraged for human health.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)